MyMD Pharmaceuticals, Inc. (MYMD)

$2.34

+0.17 (+7.83%)
Rating:
Recommendation:
-
Symbol MYMD
Price $2.34
Beta 0.287
Volume Avg. 0.06M
Market Cap 89.056M
Shares () -
52 Week Range 1.88-9.95
1y Target Est -
DCF Unlevered MYMD DCF ->
DCF Levered MYMD LDCF ->
ROE -119285.73% Strong Sell
ROA -134625.86% Strong Sell
Operating Margin -
Debt / Equity 13.16% Neutral
P/E -
P/B 4.55 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest MYMD news


Mr. Howard Yeaton
Healthcare
Biotechnology
NASDAQ Capital Market

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.